A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

Sir Keir Starmer and his health secretary have been lauding the potential of the new generation of weight-loss drugs. Given ...

A meta-analysis of over 3.7 million adults with obesity found that pancreatic cancer risk was lower for those who underwent ...

New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health ...

Weight loss drugs like Ozempic were associated with a lower risk of suicidal thoughts in teens with obesity, a new study found.

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years, according to a congressional analysis. Expanding coverage of weight-loss ...

The cost of taking weekly injections of popular anti-obesity medications liraglutide (Saxenda) or semaglutide (Wegovy) ...

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.